Ascentage Pharma Group International

ASPHFOTCHealthcare● Active

$4.53

$-0.17(-3.51%)

Market Cap$1.7B

P/E Ratio—

52W High$10.65

52W Low$4.53

Avg Volume3

Open$4.53

Beta0.65

Cash on Hand Financials Revenue

Ascentage Pharma Group International (ASPHF) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

ASPHF · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$2.47B▲ +99.9% vs prior year

FY · as of Dec 31, 2025 · Reported in CNY

Cash & Cash Equiv. (CCE)

$2.47B

cashAndCashEquivalents

Short-Term Investments

shortTermInvestments

YoY Change vs Prior Year

+99.9%

vs prior fiscal year

Latest Quarter

$2.47B

Q4 2025

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in CNY

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$2.47BCash on Hand

Total Debt$1.98BTotal Debt

Net Cash / Net Debt+$490.6MNet Cash Position

Cash vs Debt Ratio

Cash 56%Ascentage Pharma Group International cash as % of market cap: 146.12%% · MCap $2BDebt 44%

Ascentage Pharma Group International has a net cash position of $490.6M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$2.47B − $1.98B = +$490.6M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

ASPHF annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

ASPHF cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$2.47B+99.9%

Dec 31, 2024FY$1.24B+12.4%

Dec 31, 2023FY$1.10B-26.8%

Dec 31, 2022FY$1.50B-13.9%

Dec 31, 2021FY$1.75B+70.1%

ASPHF cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

ASPHF vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Ascentage Pharma Group InternationalYOU

ASPHF

$2.47B$2B146.1%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Ascentage Pharma Group International (ASPHF) cash on hand as of December 31, 2025 is $2.47B, comprising $2.47B in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Ascentage Pharma Group International cash and short-term investments on the balance sheet (10-K filing). Also referred to as Ascentage Pharma Group International cash reserves or cash position.

Ascentage Pharma Group International annual cash on hand history shows increased +99.9% in 2025: increased +99.9% in 2025. Ascentage Pharma Group International cash reserves in 2025 reflect the company's capital allocation strategy.

Ascentage Pharma Group International carries total debt of $1.98B against cash of $2.47B, resulting in a net cash position of +$490.6M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

ASPHF cash on hand · 5 questions

As of December 31, 2025, Ascentage Pharma Group International (ASPHF) has $2.47B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $2.47B in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (December 31, 2025): $2.47B. Data sourced from the annual 10-K filing via FMP.

ASPHF cash on handASPHF cash reservesASPHF cash 2025how much cash does ASPHF have

▸ Source: FMP /balance-sheet-statement · US GAAP · Ascentage Pharma Group International · Ascentage Pharma Group International SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025